Evaluation of Consistency of Treatment Response Across Regions—the LEADER Trial in Relation to the ICH E17 Guideline

Evaluation of Consistency of Treatment Response Across Regions—the LEADER Trial in Relation to the ICH E17 Guideline

The US Food and Drug Administration in 2008 required new type 2 diabetes (T2D) medications to be subject to cardiovascular outcomes safety requirements. Accordingly, the global LEADER trial investigated cardiovascular outcomes of T2D treatment with liraglutide, a glucagon-like peptide-1 receptor ago...

Full description

Bibliographic Details
Main Authors: Henrik K. Nielsen, Stephanie DeChiaro, Bryan Goldman
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Medicine
Subjects:
liraglutide
diabetes
regional
major adverse cardiovascular event
LEADER
ICH
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.662775/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.662775/full

Similar Items